Browse the evidence

Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.

To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.

Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.

Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.

If you have MASLD and diabetes or obesity, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors. These drugs not only help control blood sugar and weight but also significantly lower the risk of heart attacks and strokes, and may improve liver health. They are safe for use in MASLD patients within their approved indications.

Excess adiposity (BMI ≥30) is a causal risk factor for gastrointestinal cancers, increasing incidence and mortality through endocrine, inflammatory, and mechanical pathways.

Maintain a healthy weight to reduce your risk of gastrointestinal cancers. If you are overweight, consult your doctor about structured weight loss strategies, as obesity increases cancer risk and complicates surgical outcomes.

Obesity increases perioperative morbidity and technical complexity in gastrointestinal cancer surgery, including higher rates of anastomotic leak and surgical site infection.

If you are obese and undergoing gastrointestinal cancer surgery, discuss the increased risk of complications with your surgeon. Preoperative weight loss may be recommended to reduce these risks.

Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.

If you have overweight or obesity and are concerned about heart rhythm issues like atrial fibrillation, semaglutide therapy (up to 2.4 mg) has been shown in large studies to significantly lower that risk. This benefit appears particularly strong in patients over 60 and those treated for more than a year.

Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.

For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.

Akkermansia muciniphila supplementation in obese humans leads to greater weight loss and decreased plasma LPS levels compared to placebo, suggesting a direct microbiome-based therapy for obesity.

Akkermansia muciniphila is a specific gut bacterium that has shown promise in clinical trials for aiding weight loss in obese individuals. While not yet a formal recommendation, consuming foods that support this bacterium (like polyphenols) may be beneficial. Consult a healthcare provider before considering specific supplementation.

GLP-1 receptor agonists (GLP-1RAs) improve lipid profiles (lowering triglycerides, LDL-C, and total cholesterol, and raising HDL-C) in patients with type 2 diabetes and obesity, but these lipid-lowering effects are likely a modest contributor to their overall cardiovascular benefit.

GLP-1 medications like semaglutide and tirzepatide do improve your cholesterol and triglyceride levels, often significantly. However, their main heart-protective power comes from helping you lose weight, control blood sugar, and reduce inflammation, rather than just fixing your lipid numbers. You should still monitor your lipids, but don't expect these drugs to replace statins solely for lipid management.

Semaglutide reduces cardiovascular risk (MACE) and improves lipid profiles and blood pressure in patients with type 2 diabetes, independent of weight loss.

For patients with Type 2 Diabetes and high cardiovascular risk, semaglutide offers significant protection against major adverse cardiovascular events (heart attack, stroke, cardiovascular death) and slows kidney disease progression. It also modestly lowers blood pressure and improves lipid profiles through mechanisms independent of weight loss.

Electronic health record (EHR) data from the one-year period prior to initiating anti-obesity medication (AOM) contains sufficient multidimensional clinical signals to identify distinct obesity subtypes (clusters) with unique physiological profiles, enabling precision medicine approaches that outperform traditional BMI-based classifications.

If you are considering obesity medication, ask your doctor about 'deep phenotyping.' This means using your full medical history (labs, vitals, diagnoses) from the past year to group you into a specific 'obesity subtype.' This helps predict which medication will work best for you, rather than just using your BMI. It reduces the guesswork in choosing between different drugs like GLP-1 agonists or others.

Sustained weight loss of at least 5% achieved through pharmacotherapy or bariatric surgery is associated with a reduced risk of obesity-related cancers.

To reduce cancer risk, weight loss must be sustained over the long term. Losing at least 5% of body weight and keeping it off is associated with lower cancer risk. For those who struggle to maintain weight loss, pharmacotherapy or bariatric surgery can help sustain the loss, thereby preserving the cancer-protective benefits.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.

If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.

Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and renal events compared to placebo, demonstrating cardiovascular and renal benefits beyond glycemic control.

For patients with Type 2 Diabetes, GLP-1 medications offer protection for the heart and kidneys, reducing the risk of major cardiovascular events and kidney disease progression, independent of their weight loss effects.

Bariatric surgery (specifically Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion) provides superior long-term weight loss (average 27% over 15 years) and quality of life improvements compared to lifestyle interventions and pharmacotherapy, despite carrying higher risks of postoperative complications.

If you have a BMI over 40 (or over 35 with health issues) and lifestyle changes haven't worked, bariatric surgery is the most effective medical intervention for long-term weight loss. It involves physically altering your stomach and intestines to restrict food intake and/or absorption. While it carries surgical risks and requires lifelong vitamin monitoring, it offers the highest chance of significant, sustained weight loss and improved quality of life compared to drugs or diet alone.

Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.

If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.

GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.

GLP-1 drugs like Semaglutide help MASH by making you lose weight and improving insulin sensitivity, not by acting directly on the liver. They are approved for obesity and diabetes and show strong benefits for liver health through these indirect pathways.

GLP-1 receptor agonists (specifically liraglutide 3 mg/day) produce significant weight loss (8% mean reduction) and improve cardiovascular risk factors in obese and type 2 diabetic patients, though they carry a high discontinuation rate due to gastrointestinal side effects.

Liraglutide 3 mg daily is a highly effective pharmacological tool for weight loss, particularly for those with obesity or type 2 diabetes. It works by mimicking a gut hormone to increase satiety and slow digestion. While effective, it requires daily injections and careful dose titration to manage nausea. It is not a magic bullet; lifestyle changes are still required, and the high side-effect profile means it is not suitable for everyone.

Combination therapies (e.g., Phentermine/Topiramate, Naltrexone/Bupropion) offer superior weight loss compared to monotherapy by targeting multiple pathways (appetite suppression and calorie absorption/reward), but carry higher risks of adverse effects and require strict monitoring.

Combination drugs like Phentermine/Topiramate can achieve nearly 11% weight loss, significantly better than placebo. They work by suppressing appetite and altering brain signaling. However, they have more side effects (dry mouth, taste disturbance, insomnia) and require careful monitoring for cognitive and cardiovascular effects. They are reserved for patients who need more than single-agent therapy.

Orlistat, a lipase inhibitor, promotes modest weight loss (approx. 2-3 kg over 24 weeks) by blocking the absorption of dietary fat, but is associated with gastrointestinal side effects and potential fat-soluble vitamin deficiencies.

Orlistat is an older weight loss drug that works by blocking fat absorption. It leads to modest weight loss (around 2 kg over 6 months) and requires taking a capsule with each meal. Common side effects include oily stools and abdominal pain, which can be managed by keeping dietary fat low. You should also take a multivitamin at a different time of day to avoid nutrient deficiencies.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not impair skeletal muscle hypertrophy gains compared to placebo.

If you are doing resistance training and need pain relief, 300mg of PEA daily (split into two doses) will not hurt your muscle growth. It is a safe alternative to NSAIDs like ibuprofen, which can sometimes blunt strength gains. Take one capsule before your workout and one before bed.

Protein supplementation during endurance training significantly improves time to exhaustion (TTE) with a moderate effect size, despite having no significant effect on maximal oxygen uptake (VO2max) or body composition in the general population.

If you are doing endurance training, adding protein supplements will likely help you exercise for a longer time before exhaustion. However, do not expect this to significantly change your body weight, body fat, or maximum oxygen capacity (VO2max) unless you are currently untrained. Focus on the performance duration benefit rather than body composition changes.

Untrained individuals may experience greater improvements in maximal oxygen uptake (VO2max) from protein supplementation during endurance training compared to trained individuals.

If you are new to endurance training, adding protein supplements might help slightly improve your maximum oxygen uptake (VO2max). This benefit is likely not present if you are already a trained endurance athlete.